公司资料
Xencor 股价、新闻与催化剂
- 股票代码:
- XNCR
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
29.00 USD (+4.30%)
收盘价
最后更新: 2026年8月24日
831M USD
市值
股价为何变动
As of Aug 24, 2026, XNCR closed up 4.30% at $29.00. No new same-company headline was identified in the current news window.
公司概览
业务概览
Xencor is a biotechnology company built around antibody engineering and next-generation immunology and oncology programs. Its platform approach gives it optionality across multiple therapeutic areas.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ, Xencor sits in specialty biotechnology.
商业模式特征
The business blends partnered programs, internal development, and platform science, with valuation tied to data quality and collaboration economics.
生物医药行业定位
Xencor is a platform antibody name that can re-rate quickly when clinical data or partner progress strengthens confidence in the platform.
未来催化剂
- Xencor's catalysts are XmAb platform updates, including vudalimab and other bispecific programs that can still create partnered or internal value. The company needs data that show the platform keeps producing.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。